CCA
FBIO icon

Catalyst Capital Advisors’s Fortress Biotech FBIO Stock Holding History

Catalyst Capital Advisors’s Portfolio FBIO Stock Details FBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-2,867
Closed -$113K – 327
2013
Q4 		$113K Hold
2,867
– – 0.04% 234
2013
Q3 		$302K Buy
+2,867
New +$351K 0.17% 196

Other funds holding FBIO

EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACM
Advent Capital Management New York $4.46B AUM 0.73% 1-Year Est. Return

Catalyst Capital Advisors's FBIO Position: Q1 2014 in Review

Catalyst Capital Advisors sold out of Fortress Biotech (FBIO) in Q1 2014, closing a stake of 2,867 shares — an estimated $113K sold.

Catalyst Capital Advisors first reported a position in FBIO in Q3 2013 and held it in 2 quarters. The position peaked at $302K in Q3 2013. 57 funds tracked by Wall St. Rank hold FBIO as of Q1 2014.

  • Catalyst Capital Advisors reported no remaining Fortress Biotech position as of Q1 2014 after selling out during the quarter.
  • Catalyst Capital Advisors sold 2,867 Fortress Biotech shares in Q1 2014, an estimated $113K.
  • Catalyst Capital Advisors first reported a position in Fortress Biotech in Q3 2013 and held it in 2 quarters.
  • Catalyst Capital Advisors's Fortress Biotech position peaked at $302K in Q3 2013.
  • 57 funds tracked by Wall St. Rank held Fortress Biotech as of Q1 2014.

Based on Catalyst Capital Advisors's 13F filing for Q1 2014, filed 12 May 2014.